title: The effect of ω-fatty acids on the expression of phospholipase A2group 2A in human gastric cancer patients.
abstract: BACKGROUND
  Studies show that polyunsaturated fatty acids (PUFAs) may have an inhibitory role in carcinogenesis. It was previously shown that PLA2 group 2A (PLA2G2A) messenger RNA (mRNA) expression is associated with less frequent metastasis and longer survival in gastric adenocarcinoma. This study intends to investigate the effect of PUFAs on the expression of PLA2G2A in patients with gastric cancer.
  
  
  METHODS
  Thirty-four patients with gastric cancer (GC) were randomly divided into two groups. The first group received cisplatin medication. The second group received cisplatin medication and supplements of ω-fatty acids for three courses. The total RNA was extracted from the tissues and cDNA was synthesized. The gene expression of PLA2G2A was evaluated by the real-time polymerase chain reaction (PCR) method. To confirm the changes in gene expression, frozen section was utilized. The frozen tissue samples were sectioned and stained using the immunohistochemistry technique.
  
  
  RESULTS
  After chemotherapy and chemotherapy plus supplement, the relative mean of PLA2G2A gene expression increased 1.5 ± 0.5-fold and 7.4 ± 2.6-fold, respectively (P= 0.006). The relative mean of gene expression in patients who received cisplatin and ω-fatty acids supplement increased more significantly (7.5 ± 3.3-fold) than in patients who received only cisplatin (P= 0.016).
  
  
  CONCLUSIONS
  It was found that PUFAs increased the gene and protein expression of PLA2G2A in gastric cancer. Concerning the fact that studies reveal protective function of PLA2G2A in gastric cancer, it is suggested that increased expression of PLA2G2A is helpful. Furthermore, PUFAs can be considered as a useful therapeutic supplement for patients with gastric cancer.
authors.affiliation: Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutics Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mahboube
authors.initials: M
authors.lastname: Shariati
authors.affiliation: Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutics Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Aghaei
authors.affiliation: Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutics Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Movahedian
authors.affiliation: Department of Clinical Biochemistry, Tabriz Liver and Gastrointestinal Disease Research Center, Tabriz, Iran.
authors.forename: Mohammad Hosein
authors.initials: MH
authors.lastname: Somi
authors.affiliation: Department of Clinical Biochemistry, Tabriz Liver and Gastrointestinal Disease Research Center, Tabriz, Iran.
authors.forename: Homayun
authors.initials: H
authors.lastname: Dolatkhah
authors.affiliation: Department of Basic Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Ahmad Mirza
authors.initials: AM
authors.lastname: Aghazade
keywords: Gastric cancer (GC); phospholipase A2 (PLA2); ω-fatty acids